Deutsche Bank Ag\ Fibrogen Inc Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.73 - $2.73 $40,069 - $149,849	-54,890 Reduced 57.61%	40,394 $94,000
Q4 2023 Feb 14, 2024	BUY	$0.38 - $0.91 $36,207 - $86,708	95,284 New	95,284 $84,000
Q2 2023 Aug 14, 2023	SELL	$2.49 - $20.59 $57,401 - $474,661	-23,053 Reduced 29.77%	54,381 $146,000
Q1 2023 May 15, 2023	BUY	$15.95 - $25.18 $146,867 - $231,857	9,208 Added 13.5%	77,434 $1.44 Million
Q4 2022 Feb 13, 2023	BUY	$13.27 - $17.73 $185,992 - $248,503	14,016 Added 25.86%	68,226 $1.09 Million
Q3 2022 Nov 14, 2022	SELL	$11.4 - $14.6 $624,697 - $800,050	-54,798 Reduced 50.27%	54,210 $705,000
Q2 2022 Aug 11, 2022	BUY	$7.94 - $12.96 $294,796 - $481,178	37,128 Added 51.65%	109,008 $1.15 Million
Q1 2022 May 13, 2022	SELL	$12.02 - $16.79 $28,667 - $40,044	-2,385 Reduced 3.21%	71,880 $864,000
Q4 2021 Feb 11, 2022	BUY	$9.93 - $15.39 $30,356 - $47,047	3,057 Added 4.29%	74,265 $1.05 Million
Q3 2021 Nov 04, 2021	BUY	$10.18 - $26.64 $77,612 - $203,103	7,624 Added 11.99%	71,208 $728,000
Q2 2021 Aug 11, 2021	SELL	$18.57 - $35.68 $3.43 Million - $6.58 Million	-184,528 Reduced 74.37%	63,584 $1.69 Million
Q1 2021 May 13, 2021	SELL	$31.0 - $55.72 $499,968 - $898,652	-16,128 Reduced 6.1%	248,112 $8.61 Million
Q4 2020 Feb 16, 2021	SELL	$37.09 - $48.97 $2.71 Million - $3.58 Million	-73,129 Reduced 21.68%	264,240 $9.8 Million
Q3 2020 Nov 12, 2020	SELL	$40.47 - $45.5 $4.35 Million - $4.89 Million	-107,413 Reduced 24.15%	337,369 $13.9 Million
Q2 2020 Aug 13, 2020	BUY	$32.57 - $42.83 $9.33 Million - $12.3 Million	286,365 Added 180.77%	444,782 $18 Million
Q1 2020 May 14, 2020	BUY	$23.3 - $45.96 $30,686 - $60,529	1,317 Added 0.84%	158,417 $5.51 Million
Q4 2019 Feb 14, 2020	BUY	$34.58 - $48.06 $424,780 - $590,369	12,284 Added 8.48%	157,100 $6.74 Million
Q3 2019 Nov 14, 2019	SELL	$36.98 - $48.45 $3.04 Million - $3.98 Million	-82,133 Reduced 36.19%	144,816 $5.35 Million
Q2 2019 Aug 14, 2019	SELL	$35.13 - $55.53 $1.78 Million - $2.81 Million	-50,626 Reduced 18.24%	226,949 $10.3 Million
Q1 2019 May 15, 2019	BUY	$42.83 - $59.91 $2.32 Million - $3.25 Million	54,211 Added 24.27%	277,575 $15.1 Million
Q4 2018 Feb 14, 2019	SELL	$37.97 - $60.16 $12 Million - $19.1 Million	-317,216 Reduced 58.68%	223,364 $10.3 Million
Q3 2018 Dec 21, 2021	BUY	$56.3 - $67.25 $5.62 Million - $6.72 Million	99,854 Added 22.66%	540,580 $32.8 Million
Q3 2018 Nov 14, 2018	BUY	$56.3 - $67.25 $1.31 Million - $1.56 Million	23,224 Added 5.56%	440,726 $26.8 Million
Q2 2018 Apr 21, 2020	BUY	$44.9 - $64.95 $1.77 Million - $2.56 Million	39,344 Added 10.4%	417,502 $26.1 Million
Q2 2018 Aug 14, 2018	SELL	$44.9 - $64.95 $5.21 Million - $7.54 Million	-116,133 Reduced 23.49%	378,158 $23.7 Million
Q1 2018 Oct 18, 2019	BUY	$45.35 - $61.65 $4.97 Million - $6.76 Million	109,648 Added 28.51%	494,291 $22.8 Million
Q1 2018 May 15, 2018	BUY	$45.35 - $61.65 $502,840 - $683,575	11,088 Added 2.97%	384,643 $17.8 Million
Q4 2017 Feb 14, 2018	BUY	$41.95 - $60.1 $7.3 Million - $10.5 Million	174,126 Added 87.31%	373,555 $17.7 Million
Q3 2017 Nov 14, 2017	BUY	$33.4 - $53.9 $6.66 Million - $10.7 Million	199,429	199,429 $10.7 Million

Others Institutions Holding FGEN

# of Institutions

Shares Held

47.1M

Call Options Held

387K

Put Options Held

672K

Primecap Management CO Pasadena, CA

9.91M
Shares

$3.47 Million
0.0% of portfolio
Armistice Capital, LLC New York, NY

6.8M
Shares

$2.38 Million
0.05% of portfolio
Vanguard Group Inc Valley Forge, PA

5.88M
Shares

$2.06 Million
0.0% of portfolio
Acadian Asset Management LLC Boston, MA

3.91M
Shares

$1.37 Million
0.0% of portfolio
Black Rock Inc. New York, NY

2.41M
Shares

$843,377
0.0% of portfolio

View Full List

About FIBROGEN INC

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

More about FGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account